Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies
- Written by PR Newswire
SHANGHAI, Dec. 27, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to develop series of targeted radiopharmaceutical therapy ("TRT") products. Under the agreement. Yonghe as the CDMO partner will provide...













